Back to search

Article

A Phase I Dose-Escalation Study of Lobaplatin Combined with Paclitaxel in Platinum-Sensitive Recurrent Ovarian Epithelial Carcinoma: Safety, Tolerability, and Preliminary Efficacy Analysis

2025-07-18

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>: Platinum-Sensitive Recurrent Ovarian Epithelial Carcinoma (PSROC) is challenging to treat due to cumulative toxicity and resistance to platinum rechallenge. Lobaplatin (LBP), a third-generation platinum agent, offers advantages such as lower nephrotoxicity and lack of cross-resistance with carboplatin. <bold>Methods</bold>: Twelve patients were entered to three...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
a7d40dfc-c799-5367-a917-f353087ee63b
DOI
10.21203/rs.3.rs-7127907/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
A Phase I Dose-Escalation Study of Lobaplatin Combined with Paclitaxel in Platinum-Sensitive Recurrent Ovarian Epithelial Carcinoma: Safety, Tolerability, and Preliminary Efficacy AnalysisDOI 10.21203/rs.3.rs-7127907/v1
A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)Semantic proximity
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysis.Semantic proximity
Durable Disease Control after Sequential Anlotinib Maintenance Therapy Following Local Radiotherapy in a Patient with Platinum-Refractory Recurrent Ovarian Clear Cell Carcinoma: A Case Report and Literature ReviewSemantic proximity
Phase II proof-of-concept study of durvalumab and cediranib with and without olaparib in recurrent ovarian cancerSemantic proximity
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer.Semantic proximity
The Drug-Resistance Mechanisms of Five Platinum-Based Antitumor AgentsSemantic proximity
The safety and efficacy of nedaplatin and lobaplatin combined with pemetrexed in first-line chemotherapy for locally advanced and advanced lung adenocarcinoma - A retrospective studySemantic proximity
Phase I/Ib study of olaparib and carboplatin in women with triple negative breast cancerSemantic proximity
Carboplatin: molecular mechanisms of action associated with chemoresistanceSemantic proximity
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.Semantic proximity
A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies.Semantic proximity
Olaparib as treatment for platinum‐sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency: Phase 2 LIGHT study final overall survival analysisSemantic proximity
Select a neighboring publication to make it the new centre.